2000, ISBN 185317775X, viii, 270
Book
Thrombosis Research, ISSN 0049-3848, 2010, Volume 127, Issue 6, pp. 497 - 504
Abstract Although results of some phase III clinical trials of new oral anticoagulants are now known, it is important to understand the mechanisms of their...
Hematology, Oncology and Palliative Medicine | Direct thrombin inhibitors | Anticoagulants | Rivaroxaban | Direct Factor Xa inhibitors | DIRECT THROMBIN INHIBITOR | BAY 59-7939 | TOTAL KNEE REPLACEMENT | IN-VITRO | VENOUS THROMBOEMBOLISM | DABIGATRAN ETEXILATE | TOTAL HIP | POPULATION PHARMACOKINETICS | DOUBLE-BLIND | PERIPHERAL VASCULAR DISEASE | HEMATOLOGY | PROCOAGULANT ACTIVITY | Animals | Blood Coagulation - drug effects | Factor Xa Inhibitors | Anticoagulants - pharmacology | Humans | Blood Coagulation Tests | Morpholines - pharmacology | Thiophenes - pharmacology | Glycosaminoglycans | Medical examination | Cytochrome P-450 | Prothrombin | Thrombin | Anticoagulants (Medicine) | Comparative analysis | Blood
Hematology, Oncology and Palliative Medicine | Direct thrombin inhibitors | Anticoagulants | Rivaroxaban | Direct Factor Xa inhibitors | DIRECT THROMBIN INHIBITOR | BAY 59-7939 | TOTAL KNEE REPLACEMENT | IN-VITRO | VENOUS THROMBOEMBOLISM | DABIGATRAN ETEXILATE | TOTAL HIP | POPULATION PHARMACOKINETICS | DOUBLE-BLIND | PERIPHERAL VASCULAR DISEASE | HEMATOLOGY | PROCOAGULANT ACTIVITY | Animals | Blood Coagulation - drug effects | Factor Xa Inhibitors | Anticoagulants - pharmacology | Humans | Blood Coagulation Tests | Morpholines - pharmacology | Thiophenes - pharmacology | Glycosaminoglycans | Medical examination | Cytochrome P-450 | Prothrombin | Thrombin | Anticoagulants (Medicine) | Comparative analysis | Blood
Journal Article
Blood, ISSN 0006-4971, 12/2014, Volume 124, Issue 21, pp. 2868 - 2868
Abstract Specific anti-activated factor X molecules are currently used for the prevention and the treatment of various thromboembolic disorders. However,...
Journal Article
Chest, ISSN 0012-3692, 2012, Volume 141, Issue 2, pp. e24S - e43S
This article describes the pharmacology of approved parenteral anticoagulants. These include the indirect anticoagulants, unfractionated heparin (UFH),...
RESPIRATORY SYSTEM | CRITICAL CARE MEDICINE | Heparitin Sulfate - adverse effects | United States | Humans | Thrombin - antagonists & inhibitors | Heparin - administration & dosage | Heparin, Low-Molecular-Weight - adverse effects | Recombinant Proteins - adverse effects | Heparin - adverse effects | Hirudins - administration & dosage | Dose-Response Relationship, Drug | Pipecolic Acids - administration & dosage | Chondroitin Sulfates - adverse effects | Societies, Medical | Pipecolic Acids - adverse effects | Heparitin Sulfate - administration & dosage | Polysaccharides - administration & dosage | Thrombosis - blood | Thrombosis - prevention & control | Dermatan Sulfate - administration & dosage | Dermatan Sulfate - adverse effects | Peptide Fragments - administration & dosage | Polysaccharides - adverse effects | Evidence-Based Medicine | Recombinant Proteins - administration & dosage | Antithrombins - agonists | Chondroitin Sulfates - administration & dosage | Hirudins - adverse effects | Fibrinolytic Agents - administration & dosage | Peptide Fragments - adverse effects | Thrombosis - drug therapy | Heparin, Low-Molecular-Weight - administration & dosage | Infusions, Intravenous | Practice Guidelines as Topic | Antithrombotic Therapy and Prevention of Thrombosis, 9th Ed | American College of Chest Physician Evidence-Based Clinical Practice Guidelines Online Only
RESPIRATORY SYSTEM | CRITICAL CARE MEDICINE | Heparitin Sulfate - adverse effects | United States | Humans | Thrombin - antagonists & inhibitors | Heparin - administration & dosage | Heparin, Low-Molecular-Weight - adverse effects | Recombinant Proteins - adverse effects | Heparin - adverse effects | Hirudins - administration & dosage | Dose-Response Relationship, Drug | Pipecolic Acids - administration & dosage | Chondroitin Sulfates - adverse effects | Societies, Medical | Pipecolic Acids - adverse effects | Heparitin Sulfate - administration & dosage | Polysaccharides - administration & dosage | Thrombosis - blood | Thrombosis - prevention & control | Dermatan Sulfate - administration & dosage | Dermatan Sulfate - adverse effects | Peptide Fragments - administration & dosage | Polysaccharides - adverse effects | Evidence-Based Medicine | Recombinant Proteins - administration & dosage | Antithrombins - agonists | Chondroitin Sulfates - administration & dosage | Hirudins - adverse effects | Fibrinolytic Agents - administration & dosage | Peptide Fragments - adverse effects | Thrombosis - drug therapy | Heparin, Low-Molecular-Weight - administration & dosage | Infusions, Intravenous | Practice Guidelines as Topic | Antithrombotic Therapy and Prevention of Thrombosis, 9th Ed | American College of Chest Physician Evidence-Based Clinical Practice Guidelines Online Only
Journal Article
Drug Development Research, ISSN 0272-4391, 12/2013, Volume 74, Issue 8, pp. 582 - 586
Journal Article
British Journal of Haematology, ISSN 0007-1048, 01/2004, Volume 124, Issue 1, pp. 80 - 85
The in vitro closure time (CT), determined by the Platelet Function Analyzer (PFA-100(TM)), is used to monitor patients treated with aspirin. A relatively high...
Aspirin resistance | Closure time (PFA-100â„¢) | Von Willebrand factor | aspirin resistance | LOW-DOSE ASPIRIN | closure time (PFA-100(TM)) | BLEEDING-TIME | von Willebrand factor | PLATELET-FUNCTION ANALYZER | CARDIOVASCULAR-DISEASE | SENSITIVITY | DISORDERS | HEMATOLOGY | von Willebrand Factor - analysis | Prospective Studies | Platelet Function Tests - methods | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Male | Aspirin - administration & dosage | von Willebrand Factor - physiology | Platelet Aggregation Inhibitors - administration & dosage | Cardiovascular Diseases - blood | Adult | Female | Aged | Drug Resistance
Aspirin resistance | Closure time (PFA-100â„¢) | Von Willebrand factor | aspirin resistance | LOW-DOSE ASPIRIN | closure time (PFA-100(TM)) | BLEEDING-TIME | von Willebrand factor | PLATELET-FUNCTION ANALYZER | CARDIOVASCULAR-DISEASE | SENSITIVITY | DISORDERS | HEMATOLOGY | von Willebrand Factor - analysis | Prospective Studies | Platelet Function Tests - methods | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Male | Aspirin - administration & dosage | von Willebrand Factor - physiology | Platelet Aggregation Inhibitors - administration & dosage | Cardiovascular Diseases - blood | Adult | Female | Aged | Drug Resistance
Journal Article
La Presse Medicale, ISSN 0755-4982, 06/2012, Volume 41, Issue 6, pp. 557 - 559
Journal Article
Thrombosis and Haemostasis, ISSN 0340-6245, 10/2007, Volume 98, Issue 4, pp. 756 - 764
Venous thromboembolism (VTE) is often asymptomatic, mis-diagnosed, and unrecognized at death, and there is a lack of routine postmortem examinations. These...
Deep-vein thrombosis | pulmonary embolism | VTE prophylaxis | venous thromboembolism | post-thrombotic syndrome | pulmonary hypertension | Pulmonary embolism | Pulmonary hypertension | Venous thromboembolism | Post-thrombotic syndrome | COST-EFFECTIVENESS ANALYSIS | RISK-FACTORS | LONG-TERM COMPLICATIONS | FOLLOW-UP | POSTTHROMBOTIC SYNDROME | MOLECULAR-WEIGHT HEPARIN | PULMONARY-EMBOLISM | deep-vein thrombosis | MAJOR ORTHOPEDIC-SURGERY | MEDICAL PATIENTS | PERIPHERAL VASCULAR DISEASE | HEMATOLOGY | Hypertension, Pulmonary - mortality | Venous Thromboembolism - mortality | Europe | Humans | Venous Thrombosis - mortality | Anticoagulants - therapeutic use | Male | Risk | Hypertension, Pulmonary - epidemiology | Pulmonary Embolism - epidemiology | Morbidity | Pulmonary Embolism - mortality | Postthrombotic Syndrome - epidemiology | Postthrombotic Syndrome - mortality | Algorithms | Hospitals | Venous Thrombosis - epidemiology | Female | Registries | Venous Thromboembolism - epidemiology | Anticoagulants | Venous Thrombosis | Hypertension, Pulmonary | Postthrombotic Syndrome | Life Sciences | Human health and pathology | Venous Thromboembolism | Pulmonary Embolism | Medical and Health Sciences | Medicin och hälsovetenskap | Respiratory disease | Mortality | Post-thrombotic disease | Deep vein thrombosis | Cardiovascular disease | MEDICINE | Venous disease | Vascular disease | Prevention | MEDICIN | Venous thrombosis | Thromboembolism
Deep-vein thrombosis | pulmonary embolism | VTE prophylaxis | venous thromboembolism | post-thrombotic syndrome | pulmonary hypertension | Pulmonary embolism | Pulmonary hypertension | Venous thromboembolism | Post-thrombotic syndrome | COST-EFFECTIVENESS ANALYSIS | RISK-FACTORS | LONG-TERM COMPLICATIONS | FOLLOW-UP | POSTTHROMBOTIC SYNDROME | MOLECULAR-WEIGHT HEPARIN | PULMONARY-EMBOLISM | deep-vein thrombosis | MAJOR ORTHOPEDIC-SURGERY | MEDICAL PATIENTS | PERIPHERAL VASCULAR DISEASE | HEMATOLOGY | Hypertension, Pulmonary - mortality | Venous Thromboembolism - mortality | Europe | Humans | Venous Thrombosis - mortality | Anticoagulants - therapeutic use | Male | Risk | Hypertension, Pulmonary - epidemiology | Pulmonary Embolism - epidemiology | Morbidity | Pulmonary Embolism - mortality | Postthrombotic Syndrome - epidemiology | Postthrombotic Syndrome - mortality | Algorithms | Hospitals | Venous Thrombosis - epidemiology | Female | Registries | Venous Thromboembolism - epidemiology | Anticoagulants | Venous Thrombosis | Hypertension, Pulmonary | Postthrombotic Syndrome | Life Sciences | Human health and pathology | Venous Thromboembolism | Pulmonary Embolism | Medical and Health Sciences | Medicin och hälsovetenskap | Respiratory disease | Mortality | Post-thrombotic disease | Deep vein thrombosis | Cardiovascular disease | MEDICINE | Venous disease | Vascular disease | Prevention | MEDICIN | Venous thrombosis | Thromboembolism
Journal Article
Thrombosis Research, ISSN 0049-3848, 2012, Volume 130, pp. S183 - S183
Journal Article
Thrombosis Research, ISSN 0049-3848, 2012, Volume 130, pp. S190 - S190
Journal Article
Chest, ISSN 0012-3692, 2012, Volume 141, Issue 2, pp. e120S - e151S
This article focuses on new antithrombotic drugs that are in or are entering phase 3 clinical testing. Development of these new agents was prompted by the...
RESPIRATORY SYSTEM | CRITICAL CARE MEDICINE | Drugs, Investigational - adverse effects | United States | Humans | Drugs, Investigational - pharmacokinetics | Drugs, Investigational - therapeutic use | Anticoagulants - therapeutic use | Drug Approval | Anticoagulants - adverse effects | Evidence-Based Medicine | Randomized Controlled Trials as Topic | Fibrinolytic Agents - adverse effects | Clinical Trials, Phase III as Topic | Societies, Medical | Fibrinolytic Agents - pharmacokinetics | Fibrinolytic Agents - therapeutic use | Anticoagulants - pharmacokinetics | Platelet Aggregation Inhibitors - pharmacokinetics | Thrombosis - drug therapy | Thrombosis - blood | Thrombosis - prevention & control | Platelet Aggregation Inhibitors - therapeutic use | Platelet Aggregation Inhibitors - adverse effects | Practice Guidelines as Topic | Antithrombotic Therapy and Prevention of Thrombosis, 9th Ed | American College of Chest Physician Evidence-Based Clinical Practice Guidelines Online Only
RESPIRATORY SYSTEM | CRITICAL CARE MEDICINE | Drugs, Investigational - adverse effects | United States | Humans | Drugs, Investigational - pharmacokinetics | Drugs, Investigational - therapeutic use | Anticoagulants - therapeutic use | Drug Approval | Anticoagulants - adverse effects | Evidence-Based Medicine | Randomized Controlled Trials as Topic | Fibrinolytic Agents - adverse effects | Clinical Trials, Phase III as Topic | Societies, Medical | Fibrinolytic Agents - pharmacokinetics | Fibrinolytic Agents - therapeutic use | Anticoagulants - pharmacokinetics | Platelet Aggregation Inhibitors - pharmacokinetics | Thrombosis - drug therapy | Thrombosis - blood | Thrombosis - prevention & control | Platelet Aggregation Inhibitors - therapeutic use | Platelet Aggregation Inhibitors - adverse effects | Practice Guidelines as Topic | Antithrombotic Therapy and Prevention of Thrombosis, 9th Ed | American College of Chest Physician Evidence-Based Clinical Practice Guidelines Online Only
Journal Article
12.
Full Text
Anticoagulant therapeutics: In order not to jeopardize a potential therapeutical progress
Presse Medicale, ISSN 0755-4982, 2012, Volume 41, Issue 6, pp. 557 - 559
Journal Article
Annals of Internal Medicine, ISSN 0003-4819, 07/2010, Volume 153, Issue 1, pp. 8 - 18
Extended-duration low-molecular-weight heparin has been shown to prevent venous thromboembolism (VTE) in high-risk surgical patients. To evaluate the efficacy...
Acute Disease | Anticoagulants - administration & dosage | Double-Blind Method | Drug Administration Schedule | Humans | Middle Aged | Risk Factors | Male | Treatment Outcome | Hospitalization | Immobilization - adverse effects | Anticoagulants - adverse effects | Enoxaparin - adverse effects | Incidence | Venous Thromboembolism - prevention & control | Enoxaparin - administration & dosage | Aged, 80 and over | Adult | Female | Aged | Hemorrhage - chemically induced | Venous Thromboembolism - epidemiology | Delayed-Action Preparations
Acute Disease | Anticoagulants - administration & dosage | Double-Blind Method | Drug Administration Schedule | Humans | Middle Aged | Risk Factors | Male | Treatment Outcome | Hospitalization | Immobilization - adverse effects | Anticoagulants - adverse effects | Enoxaparin - adverse effects | Incidence | Venous Thromboembolism - prevention & control | Enoxaparin - administration & dosage | Aged, 80 and over | Adult | Female | Aged | Hemorrhage - chemically induced | Venous Thromboembolism - epidemiology | Delayed-Action Preparations
Journal Article
Drugs & Aging, ISSN 1170-229X, 3/2011, Volume 28, Issue 3, pp. 177 - 193
Elderly people with renal impairment are at high risk for venous thromboembolism (VTE) and acute coronary syndromes (ACS); however, they are also at increased...
Pharmacotherapy | Internal Medicine | Medicine & Public Health | Pharmacology/Toxicology | Geriatrics/Gerontology | Research-and-development | Fondaparinux-sodium, therapeutic use | Rivaroxaban, therapeutic use | Dabigatran-etexilate, therapeutic use | Low-molecular-weight-heparins, therapeutic use | Venous-thromboembolism, prevention | Dalteparin-sodium, therapeutic use | Renal-impairment | Deep-vein-thrombosis, prevention | Anticoagulants, therapeutic use | Elderly | Enoxaparin-sodium, therapeutic use | GLOMERULAR-FILTRATION-RATE | WAVE MYOCARDIAL-INFARCTION | COCKCROFT-GAULT FORMULA | DEEP-VEIN THROMBOSIS | PHARMACOLOGY & PHARMACY | ACUTE CORONARY SYNDROMES | VS. UNFRACTIONATED HEPARIN | PLACEBO-CONTROLLED TRIAL | THROMBIN INHIBITOR DABIGATRAN | FACTOR XA INHIBITOR | ILL MEDICAL PATIENTS | GERIATRICS & GERONTOLOGY | Kidney - drug effects | Anticoagulants - metabolism | Humans | Heparin, Low-Molecular-Weight - adverse effects | Anticoagulants - adverse effects | Kidney - metabolism | Venous Thromboembolism - complications | Venous Thromboembolism - chemically induced | Heparin, Low-Molecular-Weight - metabolism | Aged | Kidney Diseases - complications | Kidney - physiopathology | Kidney Diseases - metabolism | Platelet Aggregation Inhibitors - adverse effects | Prevention | Complications and side effects | Care and treatment | Anticoagulants (Medicine) | Dosage and administration | Kidney diseases | Thromboembolism | Drug therapy | Risk factors
Pharmacotherapy | Internal Medicine | Medicine & Public Health | Pharmacology/Toxicology | Geriatrics/Gerontology | Research-and-development | Fondaparinux-sodium, therapeutic use | Rivaroxaban, therapeutic use | Dabigatran-etexilate, therapeutic use | Low-molecular-weight-heparins, therapeutic use | Venous-thromboembolism, prevention | Dalteparin-sodium, therapeutic use | Renal-impairment | Deep-vein-thrombosis, prevention | Anticoagulants, therapeutic use | Elderly | Enoxaparin-sodium, therapeutic use | GLOMERULAR-FILTRATION-RATE | WAVE MYOCARDIAL-INFARCTION | COCKCROFT-GAULT FORMULA | DEEP-VEIN THROMBOSIS | PHARMACOLOGY & PHARMACY | ACUTE CORONARY SYNDROMES | VS. UNFRACTIONATED HEPARIN | PLACEBO-CONTROLLED TRIAL | THROMBIN INHIBITOR DABIGATRAN | FACTOR XA INHIBITOR | ILL MEDICAL PATIENTS | GERIATRICS & GERONTOLOGY | Kidney - drug effects | Anticoagulants - metabolism | Humans | Heparin, Low-Molecular-Weight - adverse effects | Anticoagulants - adverse effects | Kidney - metabolism | Venous Thromboembolism - complications | Venous Thromboembolism - chemically induced | Heparin, Low-Molecular-Weight - metabolism | Aged | Kidney Diseases - complications | Kidney - physiopathology | Kidney Diseases - metabolism | Platelet Aggregation Inhibitors - adverse effects | Prevention | Complications and side effects | Care and treatment | Anticoagulants (Medicine) | Dosage and administration | Kidney diseases | Thromboembolism | Drug therapy | Risk factors
Journal Article
Thrombosis and Haemostasis, ISSN 0340-6245, 04/2010, Volume 103, Issue 4, pp. 815 - 825
Although there is no need for routine coagulation monitoring with rivaroxaban – an oral, direct factor Xa inhibitor – a haemostasis assay might be valuable to...
fondaparinux | rivaroxaban | Clotting assays | venous thromboembolism | pharmacodynamics | Factor Xa inhibitor | New Technologies, Diagnostic Tools and Drugs | DIRECT FXA-INHIBITORS | ANTICOAGULANTS | BAY-59-7939 | ANTITHROMBOTIC AGENT | TIME | IN-VITRO | THROMBIN GENERATION | PHARMACOKINETICS | PERIPHERAL VASCULAR DISEASE | factor Xa inhibitor | HEMATOLOGY | Predictive Value of Tests | Factor Xa Inhibitors | Humans | Prothrombin Time | Fibrinolytic Agents - blood | Thiophenes - administration & dosage | Blood Coagulation Tests - standards | Drug Monitoring - methods | Morpholines - blood | Thiophenes - blood | Dose-Response Relationship, Drug | Rivaroxaban | Time Factors | Reproducibility of Results | Thrombelastography | Administration, Oral | Morpholines - administration & dosage | Morpholines - pharmacology | Thiophenes - pharmacology | Calibration | Polysaccharides - pharmacology | Drug Monitoring - standards | Fibrinolytic Agents - pharmacology | Blood Coagulation - drug effects | Partial Thromboplastin Time | Fibrinolytic Agents - administration & dosage | Thrombin - metabolism
fondaparinux | rivaroxaban | Clotting assays | venous thromboembolism | pharmacodynamics | Factor Xa inhibitor | New Technologies, Diagnostic Tools and Drugs | DIRECT FXA-INHIBITORS | ANTICOAGULANTS | BAY-59-7939 | ANTITHROMBOTIC AGENT | TIME | IN-VITRO | THROMBIN GENERATION | PHARMACOKINETICS | PERIPHERAL VASCULAR DISEASE | factor Xa inhibitor | HEMATOLOGY | Predictive Value of Tests | Factor Xa Inhibitors | Humans | Prothrombin Time | Fibrinolytic Agents - blood | Thiophenes - administration & dosage | Blood Coagulation Tests - standards | Drug Monitoring - methods | Morpholines - blood | Thiophenes - blood | Dose-Response Relationship, Drug | Rivaroxaban | Time Factors | Reproducibility of Results | Thrombelastography | Administration, Oral | Morpholines - administration & dosage | Morpholines - pharmacology | Thiophenes - pharmacology | Calibration | Polysaccharides - pharmacology | Drug Monitoring - standards | Fibrinolytic Agents - pharmacology | Blood Coagulation - drug effects | Partial Thromboplastin Time | Fibrinolytic Agents - administration & dosage | Thrombin - metabolism
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 02/2013, Volume 368, Issue 8, pp. 699 - 708
When used for extended treatment after 6 to 12 months of anticoagulation therapy for venous thromboembolism, the factor Xa inhibitor apixaban reduced the risk...
LONG-TERM | PREVENTION | MEDICINE, GENERAL & INTERNAL | ARTERIAL CARDIOVASCULAR EVENTS | INTENSITY WARFARIN THERAPY | PULMONARY-EMBOLISM | Recurrence | Pyrazoles - therapeutic use | Venous Thromboembolism - mortality | Factor Xa Inhibitors | Follow-Up Studies | Humans | Middle Aged | Male | Venous Thromboembolism - drug therapy | Creatinine - metabolism | Fibrinolytic Agents - adverse effects | Pyridones - administration & dosage | Fibrinolytic Agents - therapeutic use | Hemorrhage - etiology | Adult | Female | Pyrazoles - adverse effects | Double-Blind Method | Kaplan-Meier Estimate | Treatment Outcome | Pyrazoles - administration & dosage | Intention to Treat Analysis | Aged | Fibrinolytic Agents - administration & dosage | Pyridones - therapeutic use | Pyridones - adverse effects | Drugs | Dose-response relationship (Biochemistry) | Apixaban | Dosage and administration | Venous thrombosis | Product/Service Evaluations | Drug therapy | Anticoagulants | Heart attacks | Motivation | Clinical trials | Thromboembolism | Bone surgery | Patients | Bleeding | Blood clots | Veins & arteries | Life Sciences | Human health and pathology
LONG-TERM | PREVENTION | MEDICINE, GENERAL & INTERNAL | ARTERIAL CARDIOVASCULAR EVENTS | INTENSITY WARFARIN THERAPY | PULMONARY-EMBOLISM | Recurrence | Pyrazoles - therapeutic use | Venous Thromboembolism - mortality | Factor Xa Inhibitors | Follow-Up Studies | Humans | Middle Aged | Male | Venous Thromboembolism - drug therapy | Creatinine - metabolism | Fibrinolytic Agents - adverse effects | Pyridones - administration & dosage | Fibrinolytic Agents - therapeutic use | Hemorrhage - etiology | Adult | Female | Pyrazoles - adverse effects | Double-Blind Method | Kaplan-Meier Estimate | Treatment Outcome | Pyrazoles - administration & dosage | Intention to Treat Analysis | Aged | Fibrinolytic Agents - administration & dosage | Pyridones - therapeutic use | Pyridones - adverse effects | Drugs | Dose-response relationship (Biochemistry) | Apixaban | Dosage and administration | Venous thrombosis | Product/Service Evaluations | Drug therapy | Anticoagulants | Heart attacks | Motivation | Clinical trials | Thromboembolism | Bone surgery | Patients | Bleeding | Blood clots | Veins & arteries | Life Sciences | Human health and pathology
Journal Article
17.
Full Text
Anticoagulant therapeutics: In order not to jeopardize a potential therapeutical progress
PRESSE MEDICALE, ISSN 0755-4982, 06/2012, Volume 41, Issue 6, pp. 557 - 559
MEDICINE, GENERAL & INTERNAL | DABIGATRAN | WARFARIN | RIVAROXABAN | Rivaroxaban | Thiophenes - therapeutic use | Pyrazoles - therapeutic use | Atrial Fibrillation - drug therapy | Humans | Anticoagulants - therapeutic use | Pyridones - therapeutic use | Dabigatran | Morpholines - therapeutic use | Benzimidazoles - therapeutic use | Pyridines - therapeutic use
Journal Article
Thrombosis and Haemostasis, ISSN 0340-6245, 02/2012, Volume 107, Issue 2, pp. 379 - 387
Rivaroxaban is an oral, direct factor Xa inhibitor. Routine coagulation monitoring is not required, but a quantitative determination of rivaroxaban...
rivaroxaban | calibrators and controls | plasma levels | Anti-factor Xa assay | New Technologies, Diagnostic Tools and Drugs | Calibrators and controls | Rivaroxaban | Plasma levels | ENOXAPARIN | BAY-59-7939 | BAY 59-7939 | ARTHROPLASTY | PHARMACODYNAMICS | VENOUS THROMBOEMBOLISM | POPULATION PHARMACOKINETICS | ORAL ANTITHROMBOTICS | PERIPHERAL VASCULAR DISEASE | THROMBOPROPHYLAXIS | INHIBITOR | HEMATOLOGY | Blood Chemical Analysis - methods | Thiophenes - therapeutic use | Reproducibility of Results | Factor Xa Inhibitors | Europe | Humans | Morpholines - pharmacology | Thiophenes - pharmacology | Anticoagulants - therapeutic use | Calibration | Morpholines - blood | North America | Thiophenes - blood | Blood Chemical Analysis - standards | Anticoagulants - blood | Feasibility Studies | Anticoagulants - pharmacology | Chromogenic Compounds - chemistry | Sensitivity and Specificity | Morpholines - therapeutic use | Observer Variation
rivaroxaban | calibrators and controls | plasma levels | Anti-factor Xa assay | New Technologies, Diagnostic Tools and Drugs | Calibrators and controls | Rivaroxaban | Plasma levels | ENOXAPARIN | BAY-59-7939 | BAY 59-7939 | ARTHROPLASTY | PHARMACODYNAMICS | VENOUS THROMBOEMBOLISM | POPULATION PHARMACOKINETICS | ORAL ANTITHROMBOTICS | PERIPHERAL VASCULAR DISEASE | THROMBOPROPHYLAXIS | INHIBITOR | HEMATOLOGY | Blood Chemical Analysis - methods | Thiophenes - therapeutic use | Reproducibility of Results | Factor Xa Inhibitors | Europe | Humans | Morpholines - pharmacology | Thiophenes - pharmacology | Anticoagulants - therapeutic use | Calibration | Morpholines - blood | North America | Thiophenes - blood | Blood Chemical Analysis - standards | Anticoagulants - blood | Feasibility Studies | Anticoagulants - pharmacology | Chromogenic Compounds - chemistry | Sensitivity and Specificity | Morpholines - therapeutic use | Observer Variation
Journal Article